Pending a more complete delineation of the role of DARPP-32 in the etiology of the LNS, the findings of our study raise the possibility that targeting DARPP-32 in this disease may also be a viable therapeutic strategy. Here, PPP1R1B is linked to Lesch-Nyhan syndrome.